PRNewswire

• INOXAP's first Green Hydrogen Plant, with 190 TPA capacity, would supply 95 TPA Green Hydrogen to AIS in Phase-1
• Slated to get commissioned by July 24, the Green Hydrogen Plant will be powered by solar power 
• This will be India's first Green Hydrogen Plant for the Float Glass industry, paving way for sustainability in glass production
• The project would reduce carbon emissions by around 1250 MT annually and 25000 MT over the 20-year period

MUMBAI, India, May 10, 2024... (continue reading...)

• Sanad's sale of two CFM56-7B engines to CFM Materials highlights its ongoing commitment to strengthening industry partnerships
• By partnering with leading aftermarket specialists, Sanad reaffirms its commitment to proactive portfolio management and strategic capital allocation

HONG KONG, May 10, 2024 /PRNewswire/ -- Sanad, the global aerospace engineering and leasing solutions leader, wholly owned by Abu Dhabi's sovereign investor Mubadala Investment Company PJSC... (continue reading...)

• Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza combination vaccines and develop multiple new vaccines utilizing Novavax's Matrix-MTM adjuvant
• This agreement represents a potential multi-billion dollar revenue opportunity for Novavax including:
  • $500 million upfront payment
  • Approximately $70 million equity investment in Novavax
  • Up to $700 million in COVID-19 and combination product near-term... (continue reading...)

STOCKHOLM, May 10, 2024 /PRNewswire/ -- Skanska and its joint venture partner, B. Bell Builders, have signed a contract for a new building adjacent to McNair Hall at Rice University in Houston, Texas, USA. Skanska's share of the contract is worth USD 48M, about SEK 500M, which will be included in the US order bookings for the second quarter of 2024.

The 10,400 square meter building for the Jones Graduate School of Business at Rice University will consist of new... (continue reading...)

• Agreement provides individuals with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwards
• Provides Novavax with cash and an equity investment totalling approximately $1.2 billion (upfront payment of $500 million and up to $700 million in additional development, regulatory and launch milestones), plus tiered royalties
• Novavax is entitled to additional launch and sales milestone opportunities of up... (continue reading...)